ReviewJournal of pharmacy & bioallied sciences2025
Innovations in Cancer Immunotherapy Drug Delivery Technologies: A Systematic Review.
Review in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Innovative biomaterial solutions for enhancing the efficacy of tumor immunotherapy.Immunologic research · 2026Review
- A comprehensive review on plant-derived bioactive saponins as promising antimicrobial agents: from bioavailability challenges, molecular mechanistic insights to therapeutic applications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An innovative method in oncology, cancer immunotherapy uses the body's immune system to fight cancer cells. Despite its potential, nonspecific inflammation and autoimmunity provide major obstacles to the clinical implementation of immunotherapy. The goal of recent developments in medication delivery technology was to improve these treatments' effectiveness and safety. This systematic review explores innovative approaches such as nanoparticle-based delivery systems, biomaterial scaffolds, injectable hydrogels, transdermal delivery methods, and T-cell therapy delivery technologies. Nanoparticles are shown to improve drug localization and modulate pharmacokinetics, while biomaterials provide platforms for controlled and localized release of immunotherapies, reducing systemic toxicity. Injectable scaffolds create local immunogenic environments without requiring surgical implantation and transdermal delivery systems like microneedle patches enhance local immune activation. Advances in T-cell therapy delivery, such as DNA nanocarriers for in situ engineering and surface-conjugated nanoparticles, are intended to enhance the localization and effectiveness of adoptive T-cell therapies. Taken as a whole, these developments provide potential answers to the present problems with cancer immunotherapy, opening the door to safer and more efficient forms of treatment. Further research is essential to optimize these technologies for clinical application, ensuring long-term safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.